HealthVerity Discusses How the COVID-19 Pandemic Accelerated RWD and RWE Trends in Drug Development

The COVID-19 pandemic has hastened industry trends when it comes to using real world data (RWD) and real world evidence (RWE) to complement clinical trials. In addition to forcing researchers to think in alternative ways and to consider alternative sources of data, the pandemic has prompted pharma to consider how diversity in clinical trials can be improved.

“COVID-19 urgently highlighted the need for real-time data, and with it, the need to tap into a wider variety of data sources to answer clinical questions has become abundantly clear. Traditionally, clinical trial data is gathered by participating researchers themselves according to the study protocol, regardless of the availability of relevant “outside” information that might enhance clarity of the findings.” Read more here. 

(Source: HealthVerity, 2021)